Showing results (1201-1210 of 1,423) with videos related to

Sort By:
Pageof 143
Immunity|November 22, 2011
T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complexJarrett J Adams, Samanthi Narayanan, Baoyu Liu, et al.
American Heart Journal|December 12, 2017
Role of Doppler echocardiography for cardiac output assessment in Fontan patientsAlexander Egbe, Arooj R Khan, Sana F Khan, et al.
The American Journal of Cardiology|March 7, 2017
Outcomes of Direct Current Cardioversion in Adults With Congenital Heart DiseaseAlexander C Egbe, Samuel J Asirvatham, Heidi M Connolly, et al.
Irish Journal of Medical Science|April 22, 2022
Cost and public reimbursement of cancer medicines in the UK and the Republic of IrelandDavid O'Reilly, Ronan McLaughlin, Cian Ronayne, et al.
International Journal of Cardiology. Congenital Heart Disease|July 2, 2025
Clinical outcomes after implantation of bioprosthetic valves in adults with congenital heart diseaseAndrea R Hsu, Snigdha Karnakoti, Ahmed T Abdelhalim, et al.
Journal of the American College of Surgeons|April 16, 2011
Hepatic resection for the carcinoid syndrome in patients with severe carcinoid heart disease: does valve replacement permit safe hepatic resection?Joseph B Lillegard, James E Fisher, Travis J Mckenzie, et al.
Circulation. Arrhythmia and Electrophysiology|November 23, 2014
Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacementAnna Sabate Rotes, Heidi M Connolly, Carole A Warnes, et al.
Pediatric Neurology|September 26, 2020
Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional TestsNatalie F Miller, Lindsay N Alfano, Megan A Iammarino, et al.
Cancer Immunology Research|May 6, 2017
Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical OutcomesXinqi Wu, Jingjing Li, Erin M Connolly, et al.
Cancer|January 31, 2018
Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancerAnya Litvak, Bhavina Batukbhai, Stuart D Russell, et al.
Pageof 143